Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasting Duration Effect on Enlicitide PK in Healthy Adults
NCT06609512Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration versus Time Curve from 0 to Infinity, Area Under the Concentration versus Time Curve from Time 0 to 24 hours and 7 more. Started Oct 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06609512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609512.